The Corvidia Pipeline
We are developing ziltivekimab to potentially be the first therapy intended to reduce the risk of major cardiovascular adverse events in patients with chronic kidney disease (CKD) who have atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients in the United States who are diagnosed with moderate to severe CKD may have ASCVD and inflammation. These patients are at increased risk for an adverse cardiovascular event and there are no approved therapies to prevent this risk.
The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated across human genetic studies and preclinical studies. CANTOS, a major outcomes study published in 2017, evaluated an anti-IL1b drug that targets the same pathway as ziltivekimab in 10,000 patients. CANTOS supports our theory that reducing IL-6 could result in a significant cardiovascular benefit, specifically for patients who have reduced kidney function.
Ziltivekimab, an investigational drug, is in an ongoing Phase 2b clinical trial designed to identify the appropriate dose in order to optimize the efficacy-safety profile for patients.
We are developing COR-003 to rapidly reduce triglycerides in hospitalized patients presenting with high-triglyceride-induced acute pancreatitis (AP). High triglycerides are the third leading cause of AP. In the United States, there are an estimated 10,000 to 20,000 hospitalized cases of high triglyceride-induced AP each year¹ and there are currently no approved therapies available for its treatment.
COR-003 is an investigational therapy designed to clear triglycerides from the blood stream in two ways: it acts as the protein coding gene called apolipoprotein C2 (ApoC2) to enhance the LPL enzyme’s ability to clear triglycerides from the blood, and it works against the protein coding gene apolipoprotein C3 (ApoC3) to allow for clearance of triglycerides. COR-003 is in pre-clinical testing.